CordenPharma boosts aseptic fill-finish capacity to 500 million sterile injectable units per year
Expanded aseptic fill-finish capacity increases supply of sterile injectable medicines and related contract manufacturing output.
Source →The trace
How it reaches your house.
Starting from CordenPharma International, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
CordenPharma →supply upSterile injectable drug products
CordenPharma’s added aseptic fill-finish lines are explicitly described as increasing manufacturing capacity for sterile injectable drug products, so output availability rises.
“The expansion involves two key components to augment manufacturing capacity for sterile injectable drug products.”
97% confidenceCited →CordenPharma International →Prices riseGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Higher aseptic fill-finish throughput should lift CordenPharma’s intake of GLP-1 peptide API, but the effect is limited by the edge’s 3% share and moderate substitutability.
55% confidencePolyPeptide Group (Recipharm) →
Where it lands
What you buy, and what you own.
Goods you buy
Sterile injectable drug products · GLP-1 drugs (Ozempic, Wegovy, Mounjaro)
In the MyPRIA app, this is checked against your own holdings.